AML1ETO AML - M2 Test sale cost 1050 AED
Thalassemia Beta Mutation Analysis Test sale cost 1290 AED Thalassemia Beta Mutation Analysis Test 1,430 د.إ Original price was: 1,430 د.إ.1,290 د.إCurrent price is: 1,290 د.إ.
Del5q MDS Test sale cost 1050 AED Del5q MDS Test 1,400 د.إ Original price was: 1,400 د.إ.1,050 د.إCurrent price is: 1,050 د.إ.
Sale!

AML1ETO AML – M2 Test

Original price was: 1,400 د.إ.Current price is: 1,050 د.إ.

-25%

The AML1-ETO AML – M2 Test is a specialized diagnostic procedure aimed at detecting the presence of the AML1-ETO fusion gene, which is commonly associated with Acute Myeloid Leukemia (AML), particularly the M2 subtype. This genetic anomaly results from a translocation between chromosomes 8 and 21, which plays a significant role in the pathogenesis of the disease. The test is crucial for the accurate diagnosis, prognosis, and determination of appropriate treatment strategies for patients suspected of having AML M2.

Performed at DNA Labs UAE, a leading facility in genetic and molecular diagnostics, the test employs sophisticated techniques to ensure precise and reliable results. The cost of the AML1-ETO AML – M2 Test is set at 1050 AED, reflecting the advanced technology and expertise required to conduct this complex analysis. By identifying the specific genetic alteration, this test enables healthcare providers to tailor treatment plans more effectively, potentially improving patient outcomes in those affected by this type of leukemia.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

AML1ETO AML – M2 Test

Test Name: AML1ETO AML – M2 Test

Components: Sodium Heparin Vacutainer (2ml)

Price: 1050.0 AED

Sample Condition: Bone Marrow / Peripheral blood

Report Delivery: 3-4 days

Method: FISH

Test type: Genetics

Doctor: Oncology

Test Department:

Pre Test Information: AML1/ETO (AML – M2) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Details

AML1/ETO, also known as RUNX1/RUNX1T1, is a specific genetic abnormality that is found in a subtype of acute myeloid leukemia (AML) known as AML-M2. AML-M2 is characterized by the presence of abnormal myeloblasts (immature white blood cells) in the bone marrow.

The AML1/ETO fusion gene is formed as a result of a chromosomal translocation between the AML1 (also known as RUNX1) gene on chromosome 21 and the ETO (also known as RUNX1T1) gene on chromosome 8. This translocation leads to the fusion of the two genes, resulting in a chimeric protein known as AML1/ETO.

The AML1/ETO fusion protein interferes with normal blood cell development by disrupting the normal function of the AML1 gene. The AML1 gene is responsible for regulating the differentiation and maturation of blood cells. When the AML1/ETO fusion protein is present, it disrupts this process and promotes the accumulation of immature myeloblasts in the bone marrow, leading to the development of AML-M2.

Patients with AML-M2 with the AML1/ETO fusion gene often have a poorer prognosis compared to other subtypes of AML. However, with advancements in targeted therapies and stem cell transplantation, the prognosis for AML-M2 patients has improved in recent years.

Test Name AML1ETO AML – M2 Test
Components Sodium Heparin Vacutainer (2ml)
Price 1050.0 AED
Sample Condition Bone Marrow \/ Peripheral blood
Report Delivery 3-4 days
Method FISH
Test type Genetics
Doctor Oncology
Test Department:
Pre Test Information AML1/ETO (AML – M2) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

AML1/ETO, also known as RUNX1/RUNX1T1, is a specific genetic abnormality that is found in a subtype of acute myeloid leukemia (AML) known as AML-M2. AML-M2 is characterized by the presence of abnormal myeloblasts (immature white blood cells) in the bone marrow.

The AML1/ETO fusion gene is formed as a result of a chromosomal translocation between the AML1 (also known as RUNX1) gene on chromosome 21 and the ETO (also known as RUNX1T1) gene on chromosome 8. This translocation leads to the fusion of the two genes, resulting in a chimeric protein known as AML1/ETO.

The AML1/ETO fusion protein interferes with normal blood cell development by disrupting the normal function of the AML1 gene. The AML1 gene is responsible for regulating the differentiation and maturation of blood cells. When the AML1/ETO fusion protein is present, it disrupts this process and promotes the accumulation of immature myeloblasts in the bone marrow, leading to the development of AML-M2.

Patients with AML-M2 with the AML1/ETO fusion gene often have a poorer prognosis compared to other subtypes of AML. However, with advancements in targeted therapies and stem cell transplantation, the prognosis for AML-M2 patients has improved in recent years.

SKU: TEST-5528 Category:

Related products